6 Novel Anti-Inflammatory Drug Candidates to be Featured at Inflammation In Drug Discovery & Development Meeting, June 24-25 Princeton, NJ
PRINCETON, N.J., May 14 /PRNewswire/ -- The world inflammatory disease research community will be convening in Princeton, NJ to attend, speak, and exhibit at "Inflammation in Drug Discovery & Development," announces Strategic Research Institute. This conference will explore in detail -- research efforts to discover and develop safer and more effective therapies of rheumatoid arthritis and other inflammatory diseases & programs intended to generate next generation anti-inflammatory drugs.
This meeting will include presentations on the latest findings in preclinical & clinical development such as:
SCIO-469 & Other Kinase Inhibitors Targeting Inflammation & Fibrosis,
SCIOS INC.
D2E7: A New Era in TNF Blockade, ABBOTT LABORATORIES
NPI-1302a-3: Preclinical Development of an Orally Active Inhibitor,
NEREUS PHARMACEUTICALS
KINERET(R): IL-1 Receptor Antagonist, AMGEN INC.
ICE Inhibitors (HMR348-/VX-740): Treatment of
Inflammatory/AutoimmunDisease, VERTEX
DACLIZUMAB: A Humanized Anti-IL-2Ra (CD25) Monoclonal Antibody, PROTEIN
DESIGN LABS
The conference is organized into 4 main sections: 1) Novel Anti-TNF Proteins, 2) Advances in Small Molecule Anti-TNF Inhibitors, 3)IL-1 Receptors & Receptor Antagonists & 4) Additional Approaches for Novel Anti-Inflammatory Drugs. Featured topics on program include TNF blockers, BAFF, TACE Inhibitors, IRAK, p38 Kinase Inhibitors, Kineret, JNK Inhibitors, ICE, Traps, IKK, IL-2 Receptor Antibody, NFkB Pathway, etc.
biz.yahoo.com |
